New approach to 4-phenyl-β-aminotetralin from 4-(3-halophenyl)tetralen-2-ol phenylacetate

Mixed trifluoroacetyl phenylacetyl anhydride and 3-halostyrenes (fluoro, chloro, and bromo) or vinylcycloalkanes (cyclohexyl and cyclooctyl), undergo cascade Friedel-Crafts cycli-acylalkylation, enolization, and O-acylation to give 4-substituted tetralen-2-ol phenylacetates, without additional solvent in good yields. Base alcoholysis of 4-phenyltetralen-2-ol phenylacetate reveals the tetral-2-one for asymmetric transfer hydrogenation. Bromophenyltetralen-2-ol phenylacetate undergoes Suzuki coupling, and provides a short route to trans-4-phenyl-β-aminotetralin.     

大孔阳树脂催化合成苯乙酸酯

利用Ｄ７２，Ｄ６１大孔阳离子交换树脂为催化剂，催化合成苯乙酸异戊酯、苯乙酸丁酯、苯乙酸苄酸、苯乙酸苯乙酯、苯乙酸茴香酯。对影响反应的诸因素进行了讨论，酯收率为９０％左右。     

苯乙酸对肝癌细胞系SMMC-7721的增殖抑制作用及与RNA编辑酶ADAR1表达的相关性

为探讨苯乙酸(PA)对肝癌细胞系SMMC-7721的增殖抑制作用及其与RNA编辑酶ADAR1表达的相关性, 应用细胞计数及MTT法检测了不同浓度(0.5, 1.0, 2.0和4.0 mmol/L)PA对肝癌细胞系SMMC-7721的增殖抑制作用, 通过流式细胞术(FCM)分析了各细胞周期的细胞百分比, 应用半定量逆转录-聚合酶链式反应(RT-PCR)及免疫印迹杂交分析使用不同浓度(0.5, 1.0, 2.0 mmol/L)PA作用后肝癌细胞系SMMC-7721中RNA编辑酶ADAR1 mRNA及蛋白表达的变化. 结果表明, 肝癌细胞系SMMC-7721经不同浓度PA作用后, 增殖抑制率随作用时间延长及PA浓度增加而明显提高(P<0.05), 但2.0和4.0 mmol/L PA作用72 h后组间差异比较无统计学意义(P>0.05). 肝癌细胞系SMMC-7721中RNA编辑酶ADAR1 mRNA及蛋白表达随PA浓度增加而明显降低(P<0.05). 通过沉默SMMC-7721细胞中ADAR1的表达发现, ADAR1表达下调可有效抑制肝癌细胞增殖. 结果表明, PA可阻抑肝癌细胞系SMMC-7721细胞增殖, 且存在时间及剂量的依赖性, 作用机制与PA下调ADAR1表达相关.     

Phase-transfer catalyzed asymmetric arylacetate alkylation

Phenethyl arylacetates are alkylated under phase-transfer conditions with cinchona catalysts with alkyl halides in high yield with excellent enantioselectivity (84-99% ee) following recrystallization. Cinchonidine (CD) derived catalyst gave the (R)-product and cinchonine (CN) catalyst produced the (S)-product. The phenethyl (PE) ester group is removed, using ammonium formate and catalytic Pd/C, to give alkylated carboxylic acid products in high selectivity. The utility of the approach is demonstrated by a direct synthesis of (S)-naproxen^™.